Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Moleculin secured a Mexican patent for its lung-targeted liposomal Annamycin and reported ATM share sales and a reduced warrant exercise price.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Sep. 23, 2026This is an AI-powered summary. It may contain inaccuracies. Consid…
Moleculin Biotech obtained Mexican Patent No. 436849 covering its lung-targeted liposomal Annamycin, with protection through Nov. 23, 2040.Material DetailsContext by AI AnalystThis adds to Moleculin’s ongoing IP build while Annamycin advances in the pivotal MIRACLE AML trial. A clear positive catal…
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial OpportunityHOUSTON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., NASDAQ:MBRX (“Moleculin” or the “Company”), toda…